RecruitingNCT05234723

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

100 participants

Start Date

Jun 19, 2023

Study Type

OBSERVATIONAL

Conditions

Cytomegalovirus Infections

Summary

The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cytomegalovirus infections. The study is currently recruiting participants at 23 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(23)

MD Anderson Cancer Center

Houston, Texas, United States

Institut Jules Bordet

Brussels, Belgium

University Hospitals Leuven

Leuven, Belgium

Helsinki University Central Hospital

Helsinki, Helsinki, Finland

Centre Hospitalier Universitaire de Limoges

Limoges, Limoges, France

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bologna, Italy

Humanitas Research Hospital

Rozzano, Milano, Italy

Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT)

Palermo, Palermo, Italy

Ospedale San Martino

Genova, Italy

Policlinico di Milano

Milan, Italy

Azienda Ospedaliero-Universitaria di Modena

Modena, Italy

Azienda Ospedaliera dei Colli

Naples, Italy

Azienda Ospedale-Università Padova

Padova, Italy

AOU Città della salute e della scienza

Torino, Italy

ASST dei Sette Laghi

Varese, Italy

São João University Hospital

Porto, Portugal

Hospital Clinic

Barcelona, Spain

Instituto Maimónides de Investigación Biomédica de Córdoba

Córdoba, Spain

Gregorio Marañón General University Hospital

Madrid, Spain

University Hospital 12 de Octubre

Madrid, Spain

Centre hospitalier universitaire vaudois (CHUV)

Lausanne, Lausanne, Switzerland

University Hospital Zurich

Zurich, Switzerland

Manchester University NHS Foundation Trust

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05234723

Related Trials

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

NCT07225972

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Conditions

Summary

Eligibility

Plain Language Summary

Locations(23)

Related Trials

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

CMV-CMI in csCMVi After HSCT

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

R-MVST Cells for Treatment of Viral Infections